We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Indian firm Aurobindo Pharma has entered into a definitive agreement to sell its US subsidiary Natrol to an affiliate of New Mountain Capital in an all-cash transaction valued at Rs40.48bn ($550m).
Aurobindo Pharma has reached a definitive agreement to sell Natrol, a wholly owned subsidiary of Aurobindo Pharma US, to an affiliate of New Mountain Capital to combine with Jarrow Formulas.